News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Rhythm And Camurus Announce Positive Initial Data For Extended-Release Delivery Of Setmelanotide For The Treatment Of Rare Genetic Disorders Of Obesity 6/27/2017
Atossa Genetics (ATOS) Receives Positive Safety Committee Assessment Of First Cohort Receiving Oral Formulation Of Endoxifen In Phase I Dose Escalation Study 6/27/2017
TrovaGene (TROV) Announces Submission Of Investigational New Drug Application To Initiate Phase Ib/II Clinical Trial Of PCM-075 For Acute Myeloid Leukemia 6/27/2017
MabVax Therapeutics Commences Patient Dosing In MVT-1075 Radioimmunotherapy Phase I Clinical Trial For The Treatment Of Pancreatic, Colon And Lung Cancers 6/27/2017
Chromocell Announces Initiation Of Multiple Ascending Doses Portion Of Phase I Clinical Trial 6/27/2017
Sound Pharmaceuticals, Inc. Completes Enrollment On Meniere's Disease Clinical Trial 6/27/2017
NeuroVive (NVP) And Yungjin Pharmaceutical Company Ltd. Start Clinical Development In Genetic Mitochondrial Disease 6/27/2017
Will AbbVie (ABBV) Outsmart Biosimilars, And Can Clovis Oncology (CLVS) Win The PARP Race? 6/27/2017
A Look at the Deaths That Plagued Juno (JUNO) and Kite Pharma (KITE)'s CAR-T Trials 6/27/2017
Enanta Pharmaceuticals, Inc. Announces New Data On EDP-938, A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV), At The XIX International Symposium On Respiratory Viral Infections 6/26/2017
Synlogic Receives Fast Track Designation In U.S. For Lead Candidate, SYNB1020 6/26/2017
Semnur Announces Successful Phase I/II Trial In Patients With Radicular Pain For Its Lead Product, SP-102 6/26/2017
ImmunoGen (IMGN) Presents Data From Phase I Study Of IMGN779 In Acute Myeloid Leukemia 6/26/2017
Zynerba (ZYNE) Initiates ZYN001 Phase I Clinical Program 6/26/2017
Voyager Therapeutics (VYGR) Announces Clinical Trial Update With VY-AADC01 For Advanced Parkinson’s Disease 6/26/2017
Ablynx (ABLYF) Initiates A Single And Multiple Dose Phase I Study Of Caplacizumab In Healthy Japanese Subjects 6/26/2017
Amgen (AMGN) Goes on the Defensive When Critics Call Its Pipeline a Dud 6/23/2017
BIO2017 CARsgen Therapeutics Presented At The 2017 BIO International Convention 6/23/2017
The Lancet Oncology Publishes Anti-Leukemic Activity And Safety Data For Gilteritinib In Relapsed/Refractory Acute Myeloid Leukemia 6/23/2017
Bellicum (BLCM) Announces Clinical Data On BPX-501 At Presidential Symposium Of The 22nd Congress Of The European Hematology Association 6/23/2017
Bellicum (BLCM) Reports Clinical Results Of BPX-501 In Pediatric Leukemias At The 22nd Congress Of The European Hematology Association 6/23/2017
uniQure (QURE) Announces Clinical Data Presentations At The Upcoming International Society On Thrombosis And Hemostasis (ISTH) Congress 6/23/2017
Sunesis (SNSS) Announces Presentation Of Updated Results From Washington University-Sponsored Phase I/Cohort Expansion Trial Of Vosaroxin Plus Azacitidine In Patients With MDS At The European Hematology Association Annual Meeting 6/23/2017
Positive Phase Ib Data For NewLink Genetics (NLNK)’ IDO Pathway Inhibitor, Indoximod, In Combination With Chemotherapy For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Presented At The European Hematology Association Congress In Madrid, Spain 6/23/2017
Ionis Pharma (IONS) Release: Enrollment In Phase I/IIa Study Of IONIS-HTT Rx In Patients With Huntington's Disease Completed And Open-Label Extension Study To Open In 2H 2017 6/22/2017
Ampio Pharmaceuticals, Inc. (AMPE) Injects First Patient In Final Pivotal Clinical Trial For Ampion BLA 6/22/2017
Summit Therapeutics Presents Data From Phase I Clinical Programme Of Ezutromid At The EPNS Congress 6/22/2017
OncoArendi Therapeutics SA Announces Selection Of Its Second Clinical Development Candidate: OATD-02 For The Treatment Of Multiple Cancers 6/21/2017
RXi Pharma (RXII) Announces Completion Of Enrollment Of Phase I/II Clinical Trial With RXI-109 For Retinal Scarring 6/21/2017
Northwestern University Release: Cold Virus, Stem Cells Tested To Destroy Deadly Brain Cancer 6/21/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients 6/21/2017
Regeneus (RGS.AX) To Receive Milestone Payment For Successful Phase I 6/21/2017
BIO2017: After IPO, Full Speed Ahead for San Diego’s Tocagen 6/20/2017
Spyryx Biosciences Expands Development Award With Cystic Fibrosis Foundation; Presents Phase I Data For SPX-101 At The European Cystic Fibrosis Conference 6/20/2017
Intezyne Technologies LLC Granted Orphan Drug Designation For IT-139 In Pancreatic Cancer 6/20/2017
Evogene Ltd. (EVGN) Announces Positive Results In Insect Control Seed Trait Program And Advancement To Phase-I Of First Toxin Against Western Corn Rootworm 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
New Data Reveals This New York Biotech's Pipeline Could be a Game Changer 6/19/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines 6/19/2017
Porton Biopharma Gains Approval To Advance Next Generation Anthrax Vaccine 6/19/2017
NanoBio Corporation And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine 6/19/2017
ADC Therapeutics Presents First Clinical Data From Its Novel Antibody-Drug Conjugate ADCT-402 At The International Conference On Malignant Lymphoma 6/19/2017
MacroGenics (MGNX) Presents Updated Data From Phase I Study Of MGD010 At Annual European Congress Of Rheumatology (EULAR 2017) 6/19/2017
Pfizer (PFE) Begins Phase I Clinical Trial To Evaluate Investigational Group B Streptococcus Vaccine 6/19/2017
Synlogic Doses First Subject In Phase I Trial Of Novel Class Of Synthetic Biotic Medicines 6/19/2017
Spectrum Pharma (SPPI) Highlights Results Of A Combination Study Of FOLOTYN (Pralatrexate Injection) Plus Romidepsin Presented At The 14th International Conference On Malignant Lymphoma (14-ICML) Meeting 6/19/2017
Ammonett Pharma Granted Orphan Drug Designation From The U.S. FDA For Ibutamoren Mesylate (MK-0677) For Treatment Of Growth Hormone Deficiency 6/19/2017
Celyad Reports Promising Early Results At First Dose Level Of The Solid Arm Of The THINK Trial 6/19/2017
Juno (JUNO) Presents TRANSCEND NHL 001 Trial Data At International Conference On Malignant Lymphoma 6/19/2017
BioMarin (BMRN) Announces Acceptance Of Late Breaking Abstract At The International Society On Thrombosis And Haemostasis 2017 Congress 6/16/2017
BeiGene (BGNE) Presents Initial Phase I Data On BTK Inhibitor BGB-3111 Combined With Obinutuzumab At The 14th International Conference On Malignant Lymphoma And Announces Additional Planned Global Registrational Trials For BGB-3111 6/16/2017
ADC Therapeutics Presents Interim Data From The First Clinical Study Of Its Novel Antibody-Drug Conjugate ADCT-301 At The 14-ICML 6/16/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
Generon (Shanghai) Corporation Ltd. Announces The Initiation Of A Phase I Clinical Study For A-337, A CD3-Activating Bi-Specific Antibody Targeting Epcam To Treat Solid Tumors 6/15/2017
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN 6/15/2017
Inovio Pharma (INO) Fully Enrolls 160 Subjects In Puerto Rico For Second Zika Vaccine Phase I Trial; Continues Leadership To Advance An Effective Preventive Solution 6/15/2017
ProQR Therapeutics B.V. (PRQR) R&D Day Highlights Progress On Pipeline And Introduces Axiomer, A Novel Proprietary RNA Technology 6/15/2017
Innate Pharma (IPH.PA ) Release: Dose-Escalation Data Show Favorable Safety Profile And Promising Clinical Activity For IPH4102 6/15/2017
Innate Pharma (IPH.PA ) : Dose-Escalation Data Show Favorable Safety Profile And Promising Clinical Activity For IPH4102 6/15/2017
MabVax Therapeutics Reports Positive Phase I Results For MVT-2163 ImmunoPET Imaging Agent 6/14/2017
Helsinn And MEI Pharma (MEIP) Announce First Patient Dosed In Phase II Dose-Optimization Study Of Pracinostat And Azacitidine In Myelodysplastic Syndrome 6/14/2017
Nordic Nanovector Release: Single Dose Betalutin Continues To Show Promising Efficacy And Safety In Recurrent Indolent NHL Patients 6/14/2017
ACEA Biosciences, Inc. Announces Successful Completion Of Phase I Clinical Study Of Novel Autoimmune Disease Drug 6/14/2017
AIVITA Comments On Positive Findings From Asterias Biotherapeutics' SCiStar Trial For Spinal Cord Injury 6/14/2017
Catalyst Biosciences And ISU Abxis Complete Dosing Of First Patient Cohort In Hemophilia B Clinical Trial 6/14/2017
TG Therapeutics (TGTX) Announces Follow-Up Data For Combination Of TGR-1202 (Umbralisib) Plus Ibrutinib In Patients With Relapsed Or Refractory CLL And MCL At The 14th International Conference On Malignant Lymphoma 6/14/2017
BeiGene (BGNE) Presents Updated Phase I Data On BTK Inhibitor BGB-3111 In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At The 14th International Conference On Malignant Lymphoma 6/14/2017
Patients With Complete Paralysis Show Additional Recovery Of Arm, Hand And Finger Function At 9-Months After Treatment With Asterias Biotherapeutics' AST-OPC1 6/13/2017
Enyo Pharma Announces Successful Completion Of EYP001 First In Man Phase I Study 6/13/2017
Exelixis (EXEL) Announces Initiation Of Phase Ib Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Locally Advanced Or Metastatic Solid Tumors 6/12/2017
ProLynx Announces PLX039, A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration Of A GLP-1 Receptor Agonist 6/12/2017
Fibrocell (FCSC) Receives Rare Pediatric Disease Designation From FDA For FCX-013 For Treatment Of Localized Scleroderma 6/12/2017
Mateon Therapeutics (MATN) Provides Update On Its Clinical Trial Programs And Milestones 6/12/2017
Herantis Pharma's Clinical Study With CDNF In Parkinson's Disease Authorized In Finland, Company Expands On Development Plan 6/12/2017
Novelion (AEGR) Announces Presentation Of Metreleptin Data At American Diabetes Association 6/12/2017
Basilea (BSLN.SW) Announces Clinical Study Agreement With Adult Brain Tumor Consortium To Explore BAL101553 In Newly Diagnosed Glioblastoma 6/12/2017
ASLAN Announces TD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 6/12/2017
PharmaCyte (PMCB) Updates Shareholders On ASCO Presentation To Oncologists 6/9/2017
KemPharm (KMPH) To Present Clinical Data For KP511, An Opioid Prodrug Candidate, At The International Conference On Opioids 6/9/2017
AGTC (AGTC) Announces Topline Safety Data For X-Linked Retinoschisis Phase I/II Study 6/9/2017
Tiny Bay Area Biotech Wants to Rattle the Billion-Dollar Injectable Drug Markets With a Single Pill 6/8/2017
Bristol-Myers Squibb (BMY) Loses $4.3 Billion in Market Value After ASCO Update 6/8/2017
This Small Massachusetts Biotech Soared to a 20-Month High on Its Celgene (CELG)-Partnered Trial 6/8/2017
NeuroDerm (NDRM) Presents Six Posters At The 21st International Congress Of Parkinson’s Disease And Movement Disorders 6/8/2017
ProQR Therapeutics B.V. (PRQR) To Present QR-010 Data At The European Cystic Fibrosis Society Conference And Provides An Update On The Ongoing Phase Ib Trial 6/8/2017
Catalyst Biosciences Announces Presentations On Its Next-Generation Subcutaneous Hemophilia Product Candidates At The 2017 International Society On Thrombosis And Haemostasis (ISTH) Meeting 6/8/2017
miRagen To Present MRG-106 Phase I Clinical Trial Data At The International Conference On Malignant Lymphoma 6/8/2017
CEL-SCI (CVM) Announces New Data For Its Rheumatoid Arthritis Vaccine Candidate Published In Peer Reviewed Journal 6/8/2017
Adocia Initiates A Phase Ib Clinical Study On The Dose-Proportionality Of Biochaperone Combo In People With Type 2 Diabetes 6/8/2017
Nordic Nanovector Release: Accepted Abstract By ICML With Updated Results From Phase I/II Trial Of Betalutin In NHL Is Now Available On-Line 6/8/2017
Tyrogenex Announces Publication Of Phase I Data For X-82 For The Oral Treatment Of Neovascular Age-Related Macular Degeneration In The Journal Of The American Medical Association 6/8/2017
Cascadian Therapeutics (ONTY)’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation From FDA For Treatment Of Breast Cancer Patients With Brain Metastases 6/8/2017
Fibrocell (FCSC) Completes Dosing Of First Cohort In Phase I/II Clinical Trial Of FCX-007 Gene Therapy For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 6/8/2017
FDA Calls Y-mAbs, Memorial Sloan-Kettering Cancer Center's Pediatric Cancer Drug a Breakthrough 6/8/2017
Loxo Oncology (LOXO) Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It 6/8/2017
Adocia Announces Positive Topline Results From A Meal-Test Clinical Study Of Biochaperone Combo In People With Type 2 Diabetes 6/7/2017
Unknown Nanjing Legend Emerges as a CAR-T Phenom at ASCO 6/7/2017
Rebiotix Data Presented At ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates With Improved Microbiome Diversity 6/7/2017
InCarda Announces Positive Clinical Data Supporting Development Of Inhaled Flecainide For The Treatment Of Symptomatic Acute Events Of Paroxysmal Atrial Fibrillation (PAF) 6/7/2017
Sangamo (SGMO) And Pfizer (PFE) Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The EMA 6/7/2017
Entasis Presents Data On Third Drug Candidate, Etx0282, An Orally Available, Extended-Spectrum ?eta-Lactamase Inhibitor, At AAM Microbe 2017 6/7/2017
Sun BioPharma Announces Completion Of The Fifth Patient Cohort In The Dose Escalation Phase Ia Study Of SBP-101 For Pancreatic Cancer 6/7/2017
Mateon Therapeutics (MATN) Receives FDA Fast Track Designation For Oxi4503 In Patients With Acute Myeloid Leukemia 6/7/2017
Aptevo Therapeutics (APVO) Highlights Key Features Of Its ADAPTIR Protein Therapeutic Platform At Two Industry Conferences 6/7/2017
ObsEva (OBSV) Announces The Completion Of A Phase I PK/PD Clinical Trial Evaluating Different Doses Of OBE2109 And Add-Back Therapy 6/7/2017
Proteostasis (PTI) Announces Clinical And Regulatory Progress Across Pipeline Programs 6/7/2017
Celgene (CELG) Release: Updated Data From Phase I Trial Of OralI DHIFA (Enasidenib) Demonstrate Complete Responses And Duration Of Response In Patients With Relapsed Or Refractory AML And An IDH2 Mutation 6/7/2017
AFFiRiS AG Announces Top Line Results Of First-In-Human Clinical Study Using AFFITOPE PD03A, Confirming Immunogenicity And Safety Profile In Parkinson's Disease Patients 6/7/2017
AbbVie (ABBV) Testosterone Gel Faces Scrutiny As First Trial Begins 6/7/2017
Calithera Biosciences (CALA) Announces FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma 6/7/2017
A Small Drugmaker Is Taking An Entirely New Approach To Getting Its Cancer Drug Approved 6/6/2017
AVEO Oncology (AVEO) And Biodesix, Inc. Announce Results From Two Investigator-Sponsored Phase I Studies Of HGF Targeted Antibody Ficlatuzumab At The 2017 ASCO Annual Meeting 6/6/2017
Basilea (BSLN.SW) Announces Presentation Of Interim Phase I/IIa Clinical Data With Anticancer Drug Candidate BAL101553 At ASCO Meeting 6/6/2017
Astellas (ALPMY) Release: Exploratory Analysis Of The Phase I/II CHRYSALIS Study Of Gilteritinib Demonstrates First Molecular Response To FLT3 Inhibitor In Acute Myeloid Leukemia 6/6/2017
ImmunoCellular Therapeutics (IMUC) Announces Data From ICT-121 Phase I Trial In Recurrent Glioblastoma At ASCO 2017 6/6/2017
Boston Biomedical Presents Data For Investigational Stemness Inhibitor Amcasertib At ASCO 2017 6/6/2017
eFFECTOR Presents Phase I Data On eFT508, Its Lead Product Candidate, At ASCO 2017 6/6/2017
Agenus (AGEN)' Anti-CTLA-4 Antibody Shows Strong Safety And Tolerability 6/6/2017
Aldeyra (ALDX) Announces First Patient Enrolled In Dry Eye Disease Phase IIa Clinical Trial 6/6/2017
ESSA Pharma Presents Data From Phase I Trial Of EPI-506 At 2017 ASCO Annual Meeting 6/6/2017
Celldex (CLDX) Presents Phase I Study Of Varlilumab And Opdivo At 2017 ASCO Annual Meeting 6/6/2017
Targovax Presents Further Positive Clinical Data From TG01 Phase I/II Trial At 2017 ASCO Annual Meeting 6/6/2017
Celgene (CELG) Release: Updated Data From Phase 1 Trial Of Oral IDHIFA (Enasidenib) Demonstrate Complete Responses And Duration Of Response In Patients With Relapsed Or Refractory AML And An IDH2 Mutation 6/6/2017
NIH And Themis Bioscience Announce The Initiation Of A Clinical Trial Of A Chikungunya Vaccine 6/6/2017
Agios (AGIO) Presents Phase I Data From Dose-Escalation And Expansion Cohorts Of AG-120 (Ivosidenib) In Patients With IDH1 Mutant Positive Cholangiocarcinoma 6/6/2017
Investors Sigh With Relief as bluebird bio (BLUE), Celgene (CELG)'s CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free 6/5/2017
Down but Not Out, Juno (JUNO) Fights Back with Positive CAR-T Results in its JCAR017 Program 6/5/2017
Stock Tanks as Endocyte (ECYT) Cuts 40% of Workforce, Slashes 2 Clinical Programs 6/5/2017
Celsion (CLSN) Announces Presentation Of OVATION Study Findings At The ASCO 2017 Annual Meeting 6/5/2017
TetraPhase (TTPH) Announces Positive Phase I Single-Ascending Dose Data For Antibiotic Pipeline Candidates 6/5/2017
Loxo Oncology (LOXO) Announces Clinical Proof Of Concept Publication For Next-Generation TRK Inhibitor LOXO-195 6/5/2017
Five Prime (FPRX) Presents Updated Data From Phase I Trial Of Single-Agent FPA144 At 2017 ASCO Annual Meeting 6/5/2017
Radius Health (RDUS) Presents Positive Data From A Fully Enrolled Ongoing Phase I Study For Investigational Drug Elacestrant (RAD1901) At The 2017 ASCO 6/5/2017
Five Prime (FPRX) Presents Initial Clinical Trial Data From Phase I/II Trial Of Cabiralizumab In Pigmented Villonodular Synovitis (PVNS) At 2017 ASCO Annual Meeting 6/5/2017
ZIOPHARM Oncology (ZIOP) Announces Positive Updated Results Of Ad-RTS-Hil-12 + Veledimex In Recurrent Glioblastoma At The 2017 ASCO Annual Meeting 6/5/2017
Avivagen Provides Business Updates 6/5/2017
BeiGene (BGNE) Presents Initial Phase I Data On Anti-PD-1 Antibody BGB-A317 Combined With PARP Inhibitor BGB-290 At The 2017 ASCO Annual Meeting 6/5/2017
Calithera Biosciences (CALA) Release: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented At The ASCO Annual Meeting 6/5/2017
Tesaro (TSRO) Provides Business And Pipeline Update At ASCO Investor Briefing 6/5/2017
Achaogen (AKAO) Highlights Data Demonstrating Potential Of Plazomicin Against MDR Gram-Negative Bacteria At ASM Microbe 2017 Annual Meeting 6/5/2017
ARMO BioSciences Announces Encouraging Survival Data Observed In Patients With Advanced Pancreatic Cancer In Phase I/Ib Trial Of Immunotherapy AM0010 6/5/2017
Further Study Of Combination Of Eisai Inc. (ESALF.PK)'s Lenvatinib And Merck & Co. (MRK)'s Pembrolizumab In Previously Treated Patients With Metastatic Endometrial Cancer Supported By Interim Analysis Of Ongoing Phase Ib/II Trial 6/5/2017
ARMO BioSciences Announces Promising Response Rates And Survival Data In Patients With Advanced NSCLC And RCC From Phase I/Ib Trial For Immunotherapy AM0010 With Checkpoint Inhibitors 6/5/2017
CARsgen Therapeutics Presents Phase I Results Of CAR-GPC3 T HCC Trial At ASCO 2017 Annual Meeting 6/5/2017
MabVax Therapeutics Phase I Trial Results Of Antibody Therapy MVT-5873 For The Treatment Of Advanced Pancreatic Cancer Presented At The 2017 ASCO Annual Meeting 6/5/2017
Blueprint Medicines (BPMC) Announces New Phase I Clinical Data For BLU-285 In Advanced Gastrointestinal Stromal Tumors And Plans To Pursue Expedited Development In Patients With A PDGFRa D842V Mutation 6/5/2017
Zavante Therapeutics Presents Positive Results From NIH-Sponsored ZOLYD Phase I Trial At ASM Microbe 2017 Meeting 6/5/2017
Sierra Oncology Reports Encouraging Initial Progress From Ongoing Phase I Clinical Trials Of Chk1 Inhibitor SRA737 6/5/2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity Of Investigational Stemness Inhibitor Napabucasin In Seven Tumor Types At ASCO 2017 6/5/2017
NYU Langone Medical Center Release: Immunotherapy Drug Effective For Metastatic Triple Negative Breast Cancer 6/5/2017
Deciphera Reports Updated Phase I Clinical Study Results With DCC-2618 At 2017 ASCO Annual Meeting 6/5/2017
Seres Therapeutics (MCRB) Announces Completion Of Enrollment For SER-287 Phase IIb Study In Patients With Ulcerative Colitis 6/5/2017
Nektar Therapeutics (NKTR) Presents New Clinical Data From Two Studies Of NKTR-214, A CD122-Biased Agonist, At 2017 ASCO Annual Meeting 6/5/2017
Castle Creek Pharma Announces First Patient Enrolled In DELIVERS Study Of Diacerein 1% Ointment For Epidermolysis Bullosa Simplex 6/5/2017
Daiichi Sankyo Release: New Precision Medicine Data On DS-8201 In HER2-Expressing Breast Cancer Revealed At 2017 ASCO Annual Meeting 6/5/2017
Janssen R&D Release: Daratumumab Combination Therapy Improved Clinical Outcomes Regardless Of Cytogenetic Risk For Previously-Treated Patients With Multiple Myeloma 6/5/2017
Zymeworks Presents Safety And Anti-Tumor Activity Data From The Ongoing Phase I Study Of ZW25 At ASCO Annual Meeting (ASCO 2017) 6/5/2017
Bird Rock Bio Completes Single Ascending Dose Human Clinical Trial For Namacizumab; Generates Safety, Tolerability, And Pharmacokinetics Data; Prepares To Initiate Study In Non-Alcoholic Fatty Liver Disease Patients 6/5/2017
Kite Pharma (KITE) Reports 73 Percent Of Patients Achieved MRD Negative Complete Remission In Updated Analysis From Phase I ZUMA-3 CAR-T Trial Of KTE-C19 In Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 6/5/2017
Astellas (ALPMY) And Seattle Genetics (SGEN) Announce Updated Enfortumab Vedotin Phase I Data In Metastatic Urothelial Cancer At 2017 ASCO Annual Meeting 6/5/2017
Immune Design Corporation (IMDZ) Updates Positive Data From Lead Cancer Immunotherapy Programs At ASCO Annual Meeting 6/5/2017
Corvus Pharma Announces Interim Results Demonstrating Anti-Tumor Activity Of CPI-444 In Renal And Lung Cancer Patients Resistant Or Refractory To Prior PD-(L)1 Treatment 6/5/2017
Aileron Therapeutics Release: Anti-Tumor Activity Observed In Phase I Trial Of Novel P53-Targeting Drug ALRN-6924 6/5/2017
Nanobiotix : Promising Data From Phase I/II Head And Neck Cancer Trial With NBTXR3 Presented At The ASCO's Annual Meeting 6/5/2017
Adaptimmune (ADAP) Announces An Oral Presentation On Data From NY-ESO Study In Synovial Sarcoma And Four Trials In Progress Posters At The ASCO Annual Meeting 6/5/2017
HalioDx: Immunosign Gene Signature Assesses LTX-315 Ability To Turn 'Cold' Tumors 'Hot' At ASCO 2017 6/5/2017
Jounce (JNCE) Presents Phase I Data From ICONIC Study Of JTX-2011 In Patients With Advanced Solid Tumors At 2017 ASCO Annual Meeting 6/5/2017
TG Therapeutics (TGTX) Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO 6/5/2017
Cortice Biosciences Announces Presentation Of Final Results From The Dose Escalation Stage Of A Phase I/II Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma 6/5/2017
Spectacular Data Posted for Novartis AG (NVS)'s Next Generation CAR-T Drug 6/2/2017
Novartis AG (NVS) Lays Out R&D Game Plan at Meet and Greet With 30 Execs in Boston 6/2/2017
Corrona Announces First Patient Has Enrolled In Its Inflammatory Bowel Disease Registry 6/2/2017
DNAtrix, Inc. To Present Results Of DNX-2401 For Recurrent Glioblastoma At ASCO 6/2/2017
Novartis AG (NVS) Presents Updated Data That Reinforce The Efficacy And Safety Of Kisqali (Ribociclib) Plus Letrozole As A First-Line Option For HR+/HER2- Advanced Or Metastatic Breast Cancer 6/2/2017
Orexo (ORXOF) Receives USD 2.5 Million Milestone Payment From AstraZeneca PLC (AZN) As OX-CLI Advances Into Clinical Trials 6/2/2017
A Look at Gilead (GILD)'s Possible New Drug Strategy 6/1/2017
Global Kinetics Corporation And Parkinson's Disease Foundation Announce First Patient Enrolled In APPRISE Clinical Study For Optimization Of Parkinson's Treatment 6/1/2017
BioLineRx Reports Regulatory Submissions Of Three Phase Ib Trials For BL-8040 In Combination With Atezolizumab For Solid Tumors 6/1/2017
Pain Therapeutics (PTIE) Announces Research Publication On Alzheimer’s Disease 6/1/2017
Synthetic Genomics, Inc. Launches cGMP Suite For Pharmaceutical Quality Manufacturing Of Synthetic DNA For Advaxis (ADXS)' Clinical Trials 6/1/2017
Debiopharm Announces Results From Phase I Dose-Escalation Study Of Debio 1347/CH5183284 6/1/2017
Aduro Biotech (ADRO) Announces FDA Clearance Of Investigational New Drug Application To Evaluate The Combination Of ADU-S100 With PDR001 For The Treatment Of Solid Tumors And Lymphomas 6/1/2017
Achaogen (AKAO) Initiates C-Scape Clinical Development Program With Phase I Study Of Orally-Administered Antibacterial Candidate 6/1/2017
Adocia Launches First-in-Man Clinical Study Of BioChaperone Glucagon 6/1/2017
BioPharm Executive: Here's What to Look For at ASCO 5/31/2017
Cingulate Therapeutics Initiates First Human Clinical Trial 5/31/2017
MEI Pharma (MEIP) Announces Pre-Specified Response Rate Exceeded In Dose-Escalation Study Of ME-401 In Chronic Lymphocytic Leukemia And Follicular Lymphoma 5/31/2017
Lamellar Biomedical Ltd Recruits First Patients Into Clinical Study Assessing LAMELLEYE For Treatment Of Dry Eye Disease 5/31/2017
Medical Prognosis Institute's Spinout Oncology Venture's Second Drug Candidate In The Clinic - First Multiple Myeloma Patient In Study With APO010, An Immuno-Oncology Drug 5/31/2017
Capricor Announces Upcoming Events In Duchenne Muscular Dystrophy Program 5/31/2017
ProQR Therapeutics B.V. (PRQR) Receives Fast Track Designation From The FDA For QR-110 For Leber’s Congenital Amaurosis Type 10 5/31/2017
Catalyst Biosciences’ Factor IX Recommended For Orphan Drug Designation In Europe 5/31/2017
Imcyse Obtains Authorization To Launch Phase Ib Trial In Type 1 Diabetes 5/31/2017
Atlantic Healthcare Develops Tablet Formulations Of Alicaforsen To Treat Crohn's Disease And Ulcerative Colitis 5/30/2017
Loxo Oncology (LOXO) Announces FDA Clearance Of Investigational New Drug (IND) Application For Next-Generation TRK Inhibitor, LOXO-195 5/30/2017
100-Year-Old Drug Extremely Promising For Treating Autism, University of San Diego Study 5/30/2017
5 Big Pharmas Facing Catalysts in 2017 5/26/2017
Mallinckrodt (MNK) Highlights First Patients In Company-Sponsored Prospective Observational Registry On The Use Of H.P. Acthar Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse 5/26/2017
Protagonist (PTGX) Initiates Phase l Study with Novel Hepcidin Mimetic, PTG-300 5/25/2017
TrovaGene (TROV) Release: Phase l Safety Study Supports Planned Development Of PCM-075 In AML 5/25/2017



//-->